High Density Lipoprotein (HDL) Modulation Targets

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biochemistry

Background:

• High-density lipoprotein cholesterol (HDL-C) confers cardiovascular and longevity benefits, but pharmaceutical interventions to raise it are challenging due to strong genetic influences.
• Niacin is the most potent available pharmaceutical agent for increasing HDL-C, achieving elevations up to 35%.
• Cholesteryl ester transfer protein (CETP) and endothelial lipase (EL) are key targets in the reverse cholesterol transport pathway for raising HDL-C.

Purpose of the Study:

• To review the challenges and therapeutic targets for pharmaceutical intervention aimed at increasing HDL-C levels.
• To discuss the role of CETP and EL as targets for raising HDL-C.
• To examine the progress and setbacks in the development of CETP inhibitors.

Main Methods:

• Review of existing literature on HDL-C, reverse cholesterol transport, and pharmaceutical agents.
• Analysis of clinical trial outcomes, including the ILLUMINATE trial.
• Identification of ongoing investigations into CETP inhibitors and novel therapeutic strategies.

Main Results:

• The ILLUMINATE trial was halted due to increased mortality in patients treated with torcetrapib, a CETP inhibitor.
• Several other CETP inhibitors, including anacetrapib, JTT-705, TA-8995, DRL-17822, and JTT-302, are under investigation.
• A novel therapeutic approach involves a CETP-inhibiting vaccine (CETi-1) in phase II development to raise HDL-C levels.

Conclusions:

• Targeting CETP for HDL-C elevation presents significant challenges, as demonstrated by the torcetrapib trial.
• Ongoing research into various CETP inhibitors and novel strategies like therapeutic vaccines continues.
• Further investigation is required to determine the safety and efficacy of these interventions for cardiovascular disease management.